Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2023: -0.95

Freeline Therapeutics Holdings Plc EBIT to Fixed Assets Ratio is -0.95 for the Trailing 12 Months (TTM) ending September 30, 2023, a 24.64% change year over year. The EBIT to Fixed Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of fixed assets (property, plant, and equipment). It indicates how efficiently a company utilizes its fixed assets to generate earnings. A higher ratio suggests better earnings generation from fixed assets, indicating improved operational efficiency and potentially higher profitability.

Freeline Therapeutics Holdings Plc EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -1.26, a 63.45% change year over year.
Freeline Therapeutics Holdings Plc EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -3.45, a -39.53% change year over year.
Freeline Therapeutics Holdings Plc EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -2.48.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends